Multimodal Antiobesity Medications Yield Superior Preoperative Weight Loss
By Lori Solomon HealthDay Reporter
TUESDAY, June 18, 2024 -- Combining antiobesity medications enhances preoperative weight loss in individuals with high body mass index (BMI) preparing for metabolic surgery, according to a study presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery, held from June 9 to 13 in San Diego.
Michael Kachmar, D.O., from the Pennington Biomedical Research Center in Baton Rouge, Louisiana, and colleagues characterized the success of preoperative weight-loss therapy among patients with high BMI (≥70 kg/m2) preparing for metabolic surgery. The analysis included 113 patients.
The researchers found that length of treatment ranged from 2.7 to 364 weeks, with an average time of 72.9 days. For nonpharmacologic medically supervised weight loss, the mean percent total body weight loss (%TBWL) was 5.95 percent; %TBWL was 8.14 percent for mono-glucagon-like peptide 1 and 13.1 percent for multimodal antiobesity medication. Mean absolute BMI reductions were 7.36, 7.51, and 9.61 kg/m2, respectively. Both %TBWL and absolute BMI reduction were highest for those treated with multimodal antiobesity medication therapy for 23 to 51 weeks.
"Combining antiobesity medications may achieve much greater presurgery weight loss than other methods for those with extreme obesity," coauthor Phil Schauer, M.D., also from Pennington Biomedical, said in a statement. "Many patients who would otherwise be considered 'too sick for surgery' may now qualify."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death
WEDNESDAY, May 28, 2025 -- For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related...
Endolymphatic Sac Decompression Effective for Vertigo, Migraine
WEDNESDAY, May 28, 2025 -- For Meniere disease (MD) patients with migraine, endolymphatic sac decompression (ELSD) is effective, providing postoperative relief of vertigo and...
One-Week Radiotherapy for Breast Cancer Safe, Effective Up to 10 Years
TUESDAY, May 27, 2025 -- A five-fraction, one-week schedule of adjuvant breast radiotherapy is as safe and effective as a standard three-week schedule for patients with invasive...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.